Co-CEO Jake Junkil Been joins Industry Collaboration Session to present Neurophet's brain imaging analysis technologies, including Neurophet AQUA AD

联合首席执行官杰克·容基尔·Been参加产业合作会议，介绍Neurophet的脑成像分析技术，包括Neurophet AQUA AD。

Company accelerates partnerships with global pharmaceutical companies and neurology KOLs to drive collaboration in Alzheimer's disease clinical imaging analysis

公司加快与全球制药公司和神经学关键意见领袖的合作，推动阿尔茨海默病临床影像分析领域的协作。

SEOUL, South Korea

韩国首尔

,

，

May 21, 2025

2025年5月21日

/PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 21st that it participated in the 63rd Annual Meeting of the American Society of Neuroradiology (ASNR 2025). At the event, the company presented clinical use cases demonstrating the utility of its key brain imaging AI solutions..

/PRNewswire/ -- 专注于脑部疾病诊断和治疗的人工智能（AI）解决方案公司Neurophet（联席首席执行官：Been Jake Junkil 和 Kim Donghyeon）于21日宣布，参加了美国神经放射学会（ASNR 2025）第63届年会。在会议期间，公司展示了体现其核心脑成像AI解决方案实用性的临床应用案例。

Continue Reading

继续阅读

Jake Junkil Been, Co-CEO of Neurophet, delivering a presentation at ASNR 2025.

杰克·容基尔·Been，Neurophet公司的联合首席执行官，在ASNR 2025上发表演讲。

At the Industry Collaboration Session of the conference, Jake Junkil Been, Co-CEO of Neurophet, highlighted the key features, clinical utility, and real-world applications of 'Neurophet AQUA AD' the company's AI-powered software designed to support prescription decisions, monitor treatment and side effects of Alzheimer's disease therapies..

在会议的行业合作会议上，Neurophet公司联合首席执行官Jake Junkil Been重点介绍了“Neurophet AQUA AD”的关键特性、临床应用和现实应用，这款由人工智能驱动的软件旨在支持处方决策，并监测阿尔茨海默病治疗的过程及副作用。

Neurophet AQUA AD is a software solution that provides advanced brain imaging analysis capabilities by quantitatively analyzing MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) scans. It is specifically designed to support imaging needs during the administration of anti-amyloid antibody therapies..

Neurophet AQUA AD 是一种软件解决方案，通过对 MRI（磁共振成像）和 PET（正电子发射断层扫描）进行定量分析，提供先进的脑成像分析功能。它专门设计用于在抗淀粉样蛋白抗体治疗期间支持成像需求。

With Alzheimer's disease clinical trials accelerating across the global pharmaceutical and biotech industry, the clinical value of quantitative neuroimaging biomarkers for evaluating treatment response and safety is rapidly emerging. Following the global market launch of Alzheimer's disease treatments such as Leqembi (lecanemab) and Kisunla (donanemab), ademand for imaging-based technologies that enables adverse event monitoring and prognosis prediction is rising higher than ever..

随着阿尔茨海默病临床试验在全球制药和生物技术行业中的加速推进，定量神经影像学生物标志物在评估治疗反应和安全性方面的临床价值正在迅速显现。在诸如Leqembi（lecanemab）和Kisunla（donanemab）等阿尔茨海默病治疗药物全球上市后，对基于影像技术进行不良事件监测和预后预测的需求比以往任何时候都更加高涨。

Given the critical need for precise monitoring of ARIA (Amyloid-Related Imaging Abnormalities)—a known side effect that can occur during Alzheimer's treatment—Neurophet AQUA AD is gaining significant interest from global pharmaceutical companies and research institutions. The software is increasingly recognized for its potential as a reliable tool for analyzing clinical trial imaging data..

鉴于在阿尔茨海默病治疗过程中对已知可能发生的副作用——ARIA（淀粉样蛋白相关成像异常）进行精确监测的关键需求，Neurophet AQUA AD正引起全球制药公司和研究机构的极大兴趣。该软件因其作为分析临床试验影像数据的可靠工具的潜力而日益受到认可。

In addition to the presentation, Neurophet also showcased its key AI solutions at its exhibition booth, including Neurophet AQUA, a software platform for neurodegeneration imaging analysis, and Neurophet SCALE PET, a quantitative analysis solution for PET imaging.

除了演讲之外，Neurophet还在其展览展位上展示了其关键的AI解决方案，包括神经退行性影像分析软件平台Neurophet AQUA和用于PET成像定量分析的解决方案Neurophet SCALE PET。

By participating ASNR 2025, Neurophet aims to accelerate strategic partnerships with global pharmaceutical companies and prospective clients, while actively promoting the technological excellence and market competitiveness of its flagship products—including Neurophet AQUA AD—on the global stage. The company also plans to engage in meetings with key opinion leaders (KOLs) in the field of neurology..

通过参与ASNR 2025，Neurophet旨在加速与全球制药公司和潜在客户的战略合作，同时积极在国际舞台上推广其旗舰产品（包括Neurophet AQUA AD）的技术卓越性和市场竞争力。该公司还计划与神经病学领域的重要意见领袖（KOLs）进行会面交流。

Jake Junkil Been, Co-CEO of Neurophet said that 'Since the global launch of Alzheimer's disease treatments, the importance of ARIA monitoring in clinical settings has grown significantly and we are confident that Neurophet AQUA AD can provide optimized choice for pharmaceutical companies, medical institutions and more to help patients suffering from brain disorders..

Neurophet联合首席执行官Jake Junkil Been表示：“自从全球推出阿尔茨海默病治疗以来，临床环境中对ARIA监测的重要性显著增加。我们相信Neurophet AQUA AD能够为制药公司、医疗机构等提供优化的选择，帮助那些受脑部疾病困扰的患者。”

ASNR 2025, a conference dedicated to the field of neuroradiology, is being held in

ASNR 2025，一场致力于神经放射学领域的会议，正在举行。

Philadelphia

费城

,

，

United States

美国

. The five-day event runs from

为期五天的活动从

May 17 to 21

5月17日至21日

(local time).

（当地时间）。

About Neurophet

关于Neurophet

Neurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system..

Neurophet 专注于利用尖端人工智能 (AI) 技术开发针对脑部疾病的诊断支持、治疗指南和治疗设备的解决方案。该公司由共同首席执行官 Jake Junkil Been 和 Donghyeon Kim 于2016年创立，他们开发了下一代神经导航系统。

Major products include brain MRI analysis software 'Neurophet AQUA', PET Image Quantitative Analysis Software 'Neurophet SCALE PET', Brain imaging treatment planning software for electric and magnetic brain stimulation 'Neurophet tES/TMS LAB', Alzheimer's Disease treatment prescription and monitoring software 'Neurophet AQUA AD' for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software 'Neurophet AQUA MS'..

主要产品包括脑部MRI分析软件“Neurophet AQUA”、PET图像定量分析软件“Neurophet SCALE PET”、用于电刺激和磁刺激脑成像的治疗规划软件“Neurophet tES/TMS LAB”、阿尔茨海默病治疗处方与监测软件“Neurophet AQUA AD”以跟踪治疗效果和副作用，以及多发性硬化症图像分析软件“Neurophet AQUA MS”。

Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.

Neurophet 的首要任务是帮助患有脑部疾病的患者。基于在神经科学方面的专业知识，Neurophet 将继续挑战和成长，探索人类大脑健康，并利用人工智能技术为脑部疾病开拓解决方案。

SOURCE Neurophet

源神经phet

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用